IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation

European Journal of Haematology - Tập 92 Số 6 - Trang 471-477 - 2014
Shunichiro Yamaguchi1, Eisaku Iwanaga1, Kenji Tokunaga1, Tomoko Nanri1, Taizo Shimomura2, Hitoshi Suzushima2, Hiroaki Mitsuya1, Norio Asou1
1Department of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan
2Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan

Tóm tắt

AbstractWe examined the incidence and prognostic effect of IDH1 and IDH2 mutations in 233 Japanese adults with acute myeloid leukemia (AML). IDH1 R132 mutations were detected in 20 (8.6%) patients with AML. IDH2 mutations were found in 19 (8.2%, 17 R140 and two R172) patients. IDH1 and IDH2 mutations were mutually exclusive and were associated with normal karyotype AML, cytogenetic intermediate‐risk group, and NPM1 mutations. Five‐year overall survival (OS) rates were significantly lower (15.6%) in patients harboring the IDH mutations than in patients lacking the IDH mutation (32.0%) in the entire cohort of AML (P = 0.005). Among patients aged 59 yr or younger with IDH mutations, 5‐yr OS in patients who underwent allogeneic stem cell transplantation (SCT) was significantly higher than that in those not receiving allogeneic SCT (50% vs. 10.6%, P = 0.020). Of 51 patients with NPM1 mutations, there was no significant difference in 5‐yr OS rates between patients with and those without the IDH mutations. In contrast, among 175 patients lacking the NPM1 mutations, 5‐yr OS rate in patients with IDH mutations was significantly lower than that in those without IDH mutations (0% vs. 34.7%, P = <0.001). These data suggest that IDH mutations have an unfavorable effect in AML, especially AML with the NPM1 wild type and younger AML patients with IDH mutations may benefit from allogeneic SCT.

Từ khóa


Tài liệu tham khảo

10.1182/blood.V92.7.2322

10.1182/blood-2009-11-254441

Kiyoi H, 1999, Prognostic implication of FLT3 and N‐RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074

10.1182/blood.V97.8.2434

10.1056/NEJMoa041974

10.1056/NEJMoa074306

10.1182/blood-2009-07-235358

10.1056/NEJMoa0903840

10.1074/jbc.274.43.30527

10.1016/j.ccr.2010.01.020

10.1016/j.ccr.2010.11.015

10.1182/blood-2009-11-250878

10.1200/JCO.2009.27.3730

10.1200/JCO.2010.28.3762

10.1038/leu.2010.267

10.1200/JCO.2010.28.2285

10.1182/blood-2010-12-322479

10.1186/1756-8722-5-5

10.1111/j.1751-553X.2012.01422.x

10.1182/blood-2009-11-253070

10.1200/JCO.1996.14.1.204

10.1002/cncr.21493

10.1182/blood-2010-03-273243

10.1007/s12185-009-0480-5

10.1016/j.leukres.2009.08.010

10.1200/JCO.1998.16.1.78

10.1182/blood-2006-08-043992

10.1007/s12185-009-0483-2

10.1056/NEJMoa0808710

10.1038/sj.leu.2403160

10.1038/sj.leu.2403803

10.1002/gcc.20734

10.1200/JCO.2003.04.036

10.1056/NEJMoa1112304

10.1182/blood-2010-02-267955

10.1182/blood-2010-03-272146

10.1126/science.1236062

10.1126/science.1234769

Thông tin
Thông tin xuất bản

European Journal of Haematology

Tập 92 Số 6

471-477

Thông tin tác giả